BACKGROUND: It is known that cholinergic anti-inflammatory reflex regulates inflammation in peripheral tissues. Nicotinic acetylcholine receptors (nAChRs) are mediators of this anti-inflammatory pathway and also non-neuronal cells express functional nAChrs. A role for a7-subtype acetylcholine cholinergic receptor (a7nAChR) in insulin sensitivity improvement has already been shown in rodents both in vivo and in vitro. However, no data are available on a7nAChR expression in human adipocytes. OBJECTIVE: To investigate the expression and protein content of a7nAChR in human subcutaneous adipose tissue (SAT) and in isolated mature adipocytes. DESIGN: A total of 39 SAT biopsy specimens obtained from obese and normal-weight subjects were used to assess a7nAChR messenger RNA levels and to stimulate a7nAChR with a specific agonist and antagonist in vitro. Additional SATs from eight non-diabetic obese subjects were also studied, before and after a 3-month lifestyle intervention. RESULTS: a7nAChR expression was significantly lower in the SAT of obese subjects compared with that of normal-weight subjects. In mature adipocytes isolated from morbidly obese subjects (body mass index440 kg m À2 ), a7nAChR expression was 75% lower compared with adipocytes from normal-weight subjects. In adipocytes of obese subjects, a7nAChR was downregulated also at protein level. In eight non-diabetic obese subjects, a lifestyle intervention (3 months of diet and physical activity) induced a significant weight loss and an increase in a7nAChR SAT expression. In vitro stimulation of adipocytes with the specific a7nAChR agonist PNU282987 induced a significant anti-inflammatory effect. Furthermore, a similar downregulation of the inflammatory profile, associated with a significant increase in a7nAChR protein level, was observed after genistein stimulation. CONCLUSIONS: These results provide evidence that a7nAChR expression levels are significantly decreased in obese subjects, and that this receptor modulates inflammatory gene expression in human adipocytes. The upregulation of a7nAChR by genistein stimulation opens new insights for the management of low-grade inflammation linked to human obesity.
INTRODUCTION
Low-grade chronic inflammation is associated with severe human obesity and the onset of insulin resistance and Type 2 diabetes. 1 --5 This inflammatory state is characterized by an increased number of macrophages infiltrating the adipose tissue, together with an overproduction of inflammatory cytokines. 3, 6 At present, factors triggering the inflammatory responses are not fully understood, especially in humans. 3, 6 It is known that the neural reflexes, via the vagus nerve, can attenuate systemic inflammatory responses. 7, 8 This physiological mechanism, defined as the 'cholinergic anti-inflammatory pathway', has major implications in immunology and in therapeutics. 7,9 --11 Nicotinic receptors, most concentrated in the nervous system, but also found throughout the body, are the mediators of this 'cholinergic anti-inflammatory pathway'. 12 The a7-subtype acetylcholine cholinergic receptor (a7nAChR) is involved in cognitive processes 10, 13 and is present in circulating macrophages and immune cells, where it regulates the release of inflammatory cytokines such as tumor necrosis factor alpha (TNFa), interleukin-1 (IL1) and IL18. 10 In rat adipocytes, longterm stimulation of a7nAChR has been shown to improve insulin sensitivity by modulating adipokine secretion, 14 and in a mouse model of diabetes, a specific a7nAChR agonist was shown to reduce body weight and improve metabolic parameters.
14 These findings led to consider a7nAChR as a potential therapeutic target for treating the inflammatory components of obesity. 8 In humans, expression of a7nAChR in non-neural cells has been demonstrated in cultured bronchial epithelial cells 15 and aortic endothelial cells, 16 but the role of the 'cholinergic anti-inflammatory pathway' in adipose tissue has been poorly investigated. 8 In particular, there are no studies focusing on expression of a7nAChR in human adipocytes.
In the present study, we evaluated a7nAChR expression levels in whole subcutaneous adipose tissue (SAT) obtained from a cohort of morbidly obese subjects and from a group of normalweight, never-obese healthy individuals. a7nAChR expression and its protein content were also assessed in isolated fully-mature adipocytes. We also investigated whether a7nAChR expression could be modulated in the SAT of obese patients after a 3-month lifestyle-intervention program; in addition, we studied the in vitro effects of a7nAChR stimulation.
MATERIALS AND METHODS

Patients and adipose tissue samples
A total of 39 human SAT samples were collected from 13 normal-weight subjects body mass index (BMI) (mean ± s.d.): 23.5 ± 1.51 kg m À2 , age (mean±s.d.): 44.4±7.9 years, female/male number: 7/6 during laparotomic surgery for non-inflammatory disease and from 26 obese patients (BMI: 34.5 ± 7.8 kg m À2 , age: 38.7 ± 1.7 years, female/male number:
16/10) during bariatric surgery (laparoscopic Roux-en-Y gastric bypass) interventions. Normal-weight subjects had a history of stability before surgery. Antidiabetic therapy, liver and renal dysfunction, and acute/ chronic inflammatory diseases were the exclusion criteria. Adipose samples were stored in Dulbecco's modified Eagle's medium (Invitrogen Corporation, Jefferson City, MO, USA) containing 2% bovine serum albumin (Sigma, St Louis, MO, USA), penicillin (100 U ml À1 Invitrogen Corporation), streptomycin (100 mg ml À1 Invitrogen Corporation), transported to the laboratory and immediately processed for total-RNA extraction and adipocyte isolation. Additional SAT samples were collected from eight non-diabetic obese patients (BMI: 39.7 ± 5.1, age: 48.2 ± 8.7 years, mean ± SD; female/ male: 5/3) who entered a 3-month weight-reducing program. Patients underwent physical examination, blood sample collection for measurement of high-density lipoprotein-cholesterol, triglycerides, insulin, adiponectin and bio-impedance analysis (BIA 101 --RJL Systems Akern, Clinton Township, MI, USA) for body-composition assessment. A peri-umbilical abdominal needle biopsy was performed under local anaesthesia before and after the weight-reducing program to assess a7nAChR gene expression. This lifestyle intervention consisted in two educational group sessions a week with nutritionists, dieticians, physical trainers and psychologists. The alimentary diary was weekly reviewed and discussed. Twice a week, patients participated in a 1-h gym session under a trainer's guidance. This study was approved by the Ethic Committee of Istituto Auxologico Italiano and signed informed consent was obtained from all subjects after individual explanation.
Isolation of mature adipocytes
A fragment of the collected SAT biopsies was cut into small pieces and digested with 1 mg ml À1 collagenase Type 2 (Sigma) for at least 1 h at 37 1C. The digested tissue was then filtered through a sterile gauze and then with a nylon filter (BD Bioscience, Franklin Lakes, NJ, USA). Mature adipocytes were isolated by several centrifugation and washing of the floating layer. The mature adipocyte fraction was examined by light microscopy and markers of stroma vascular fraction cells and macrophages were tested by real-time quantitative PCR to exclude the presence of 'contaminating' non-adipose cells. Adipocytes were homogenized and stored in RLT buffer (Rneasy Mini Kit, QIAGEN Protocol, Valencia, CA, USA) until total-RNA extraction.
Total-RNA extraction, quantification and copy DNA synthesis Total RNA was extracted from whole SAT biopsies, isolated adipocytes (see the previous section) and needle-SAT biopsies using the same protocol. Briefly, all adipose samples were homogenized in RLT lysis buffer (Rneasy Mini Kit, QIAGEN Protocol) using a rotator-stator, followed by a chloroform delipidation step. The upper aqueous phase was processed for total-RNA extraction using silica-based spin columns (Rneasy Mini Kit, QIAGEN Protocol). The yield of total-SAT RNA was 1.5 --7.0 mg per mg tissue. Total-RNA concentration was quantified with Nanodrop instrument (Agilent Technologies, Inc., Foster City, CA, USA) and its quality was assessed by observation of integrity of 28S and 18S ribosomal RNA (rRNA) after gel-electrophoresis migration. Copy DNA was obtained by reverse transcription with SuperScript III (Invitrogen, Carlsbad, CA, USA) starting from 1 mg of total RNA following the manufacturer's instructions.
Determination of gene expression by real-time quantitative PCR
Real-time quantitative PCR was used to quantify messenger RNA copies. For each sample, 10 ng of copy DNA template was amplified in duplicate in PCR reactions on an ABI PRISM 7700 using Assay-on-Demand gene expression products (Applied Biosystems, Foster City, CA, USA). TaqMan probes (Applied Biosystems) for a7nAChR, adiponectin, IL6, TNFa, CD68, MCP-1 (monocyte chemotactic protein-1), HP (haptoglobin) and the housekeeping gene RPLP0 (ribosomal protein large P0) labeled with carboxyfluorescein were purchased (Applied Biosystems). Analyses were performed with SDS.3 software (Applied Biosystems). For each sample, the relative amount of the target messenger RNA was normalized to the amount of ribosomal protein large P0 (RPLP0) transcript and data were expressed as 2 ÀDDCT (arbitrary units).
Specific in vitro mature adipocyte stimulation of a7nAChR
Adipose stroma vascular fraction cells were isolated as previously described and cultured with Dulbecco's modified Eagle's medium/HAM-F12 medium (Invitrogen Corporation) supplemented with 10% decomplemented foetal bovine serum (FBS, Sigma) until confluence. Confluent cells were then differentiated with Adipo Stem Pro medium (Invitrogen Corporation) for 12 days. Differentiated adipocytes were starved for 4 h before stimulation with 10 ng ml À1 lipopolysaccharides (LPS) (Sigma) for 24 h. The following day, cells were stimulated for 3 h with 1 mM PNU282987 (Sigma), a specific a7nAChR agonist. a7nAChR inhibition was tested with a 30-min preincubation with 1 mM methylcaconitine (Methyilcaconitine, Sigma), a wellknown antagonist of nicotinic cholinergic receptors. Differentiated adipocytes were also stimulated for 3 h with 5, 10 and 25 mM genistein (Sigma), a natural tyrosine kinase inhibitor.
Protein extraction and western blotting procedure
Mature adipocytes from SAT samples of five obese women (BMI 45.5±8.9 kg m À2 , age 43.0±8.12 years) and five normal-weight women (BMI 24.3±3.7 kg m À2 , age 43.4±8.09 years) were used for western blotting analysis. Cells were lysed in RIPA buffer and total protein content was then quantified with BCA protein assay kit (PIERCE, Rockford, IL, USA). One hundred micrograms of protein extract was loaded and separated by 10% SDS-polyacrylamide gel electrophoresis under denaturing conditions and then blotted on to nitrocellulose membranes (Amersham Biosciences, Little Chalfont, Buckinghamshire, UK). Membranes were blocked in TBS and 5% milk for 2 h at room temperature, incubated overnight at 4 1C in the same buffer with a goat polyclonal antibody raised against human a7nAChR (1:1000, AChRa7 (C-20), Santa Cruz Biotechnology Inc., Heidelberg, Germany) and/or a rabbit polyclonal antibody raised against human a7nAChR (1:1000, AChRa7 (H-302), Santa Cruz Biotechnology Inc.). The following day, the membranes were washed with TBS 0.1% Tween-20 and incubated for 1 h at room temperature with the secondary antibody (1:4000, horseradish peroxidase-conjugated anti-mouse antibody, Amersham Biosciences). Enhanced chemiluminescence-plus western blot detection system (Amersham Biosciences) was used for protein detection. The membranes were stripped and processed for b-actin detection (1:15000, Sigma-Aldrich, St Louis, MO, USA) in order to assess uniformity of protein loading and to estimate the relative amount. The signals were quantified by densitometric procedures and expressed as arbitrary units after normalisation on b-actin content.
Statistical analyses
All analyses were performed using GraphPad Prism version 4.02. (GraphPad Software Inc., La Jolla, CA, USA). Spearman's test was used for correlation analysis. Wilcoxon's paired test was used for mean comparisons. A P-value o0.05 was considered statistically significant.
RESULTS
Gene-expression levels of a7nAChR were significantly reduced in whole SAT of obese subjects when compared with normal-weight subjects (Figure 1a) . In the fraction of mature adipocytes isolated from the SAT of normal-weight subjects, a7nAChR expression was a7nAChR in human adipocytessix-fold higher than in whole adipose tissue (Figure 1b) . However, a7nAChR expression in isolated adipocytes of morbidly obese subjects was significantly lower than in those of normal-weight subjects (P ¼ 0.0067) ( Figure 2 ). As expected, in adipocytes from obese patients, IL6 and TNFa were upregulated and adiponectin gene was downregulated (Po0.01) (Figure 2) . In obese patients, adipocyte a7nAChR expression levels positively correlated with adiponectin expression (Rho ¼ 0.88, P ¼ 0.0076), but not with that of IL6 and TNFa. In agreement with these findings, a7nAChR protein content in adipocytes of obese subjects was significantly downregulated (À43%, P ¼ 0.016) when compared with normalweight subjects (Figure 3) . We then studied the modulation of a7nAChR gene expression in the SAT of eight non-diabetic obese patients before and after 3 months of lifestyle intervention (diet and physical activity). Table 1 shows the clinical characteristics of the patients. Mean weight loss was 4.9% and it was associated with significant improvements of some metabolic parameters. Serum adiponectin levels at the end of the intervention did not show any significant change (Table 1) . In SAT, gene-expression levels of a7nAChR after the lifestyle intervention showed a weakly significant increase (P ¼ 0.054) (Figure 4) .
Primary in vitro differentiated adipocytes were then used to assess the direct effects of a7nAChR activation on inflammatory gene expression using PNU282987, a specific agonist for a7nAChR. A pro-inflammatory activation was induced with 24-h LPS incubation, as indicated by the clear upregulation of IL6, MCP-1 and TNFa genes (Figure 5a) . A significant downregulation of these pro-inflammatory genes was observed after 3-h PNU282987 stimulation (Po0.05, Figure 5a) . A partial abrogation of the anti-inflammatory effect of a7nAChR stimulation with PNU282987 was observed with a pre-treatment of the cells with 1 mM methylcaconitine (Figure 5a ). HP and adiponectin gene expression levels were unchanged following both LPS treatment and a7nAChR stimulation/inhibition (data not shown).
It has been previously demonstrated that the tyrosine-kinase inhibitor genistein induces a rapid upregulation of a7nAChR. 17 Thus, we tested the effects of genistein stimulation on differentiated primary human adipocytes. A significant increase of a7nAChR cellular protein content was observed after 3 h treatment with 10 mM genistein (Figure 5b ). This same concentration was also used to assess pro-inflammatory gene modulation and resulted in a significantly decreased expression of IL6 and MCP-1 genes (Figure 5c ). In contrast, TNFa and HP gene expression was unaffected by genistein stimulation (data not shown).
DISCUSSION
This study shows for the first time that human mature adipocytes express a7nAChR and that its expression levels and protein content are downregulated in obesity. Furthermore, weight loss partially restores adipocyte a7nAChR expression.
A clear anti-inflammatory role for the a7nAChR expressed by macrophages and other cytokine-producing cells has been demonstrated, 10 and it is now known that this receptor is required for the anti-inflammatory effects of vagus-nerve stimulation. 10, 14 The a7nAChR can be considered to be a peripheral 'immune' component of the cholinergic anti-inflammatory pathway. 18, 19 Molecular mechanisms supporting these anti-inflammatory effects include nuclear factor kappa B pathway inhibition, 20 activation of Janus activated kinase --signal transducer and activator of transcription 21 and the consequent inhibition of TNFa production. 22 A functional role of nicotinic acetylcholine receptors (nAChRs) has already been demonstrated in rat adipocytes. 23 Nicotine treatment reduces TNFa-protein production through the activation of nAChRs, in particular the alpha-7 variant. 23 It is also known that long-term stimulation of nAChRs contributes to ameliorate insulin sensitivity and that selective a7nAChR agonists are able to reduce weight gain, food intake and plasma levels of inflammatory cytokines in rat adipocytes and in a mouse genetic model of obesity. 23, 14 These effects were completely abolished in a7nAChR KO mice treated with nicotine. 24 Although it is classically established that in humans obesity complications are principally attributable to increased visceral adipose mass and its secretion products, the results presented herein indicate that SAT might contribute to maintain the chronic low-grade inflammation, particularly in extreme obesity. Indeed, the decreased expression of a7nAChR in adipocytes may represent a new link between an impaired cholinergic antiinflammatory pathway and severity of inflammation observed in obesity.
Several pro-inflammatory factors are preferentially expressed in SAT rather than in visceral adipose tissue (that is, serum amyloid A (SAA), TNFa, Cathepsin S, and so on) in strict correlation with fat-cell size and BMI. 6 As SAT adipocytes are generally more hypertrophic than omental adipocytes, an involvement of adipocyte hypertrophy in the observed downregulation of a7nAChR, with a consequent disruption of the anti-inflammatory pathway, might be hypothesized. We also found an association between a7nAChR expression levels and adiponectin geneexpression levels in isolated adipocytes. It is well known that decreased adiponectin levels are linked to obesity and obesity co-morbidities, especially the inflammation-induced insulin resistance. Taking together these observations, it is tempting to speculate that, as for adiponectin, the decreased expression a7nAChR may represent another feature of obesity complications. However, further studies are needed to understand better the role a7nAChR in human adipocytesof this receptor in adipocyte biology and the molecular mechanism underlying its downregulation in obese patients. Interestingly, we observed an upregulation of a7nAChR in SAT after 3-month lifestyle intervention, suggesting that the cholinergic anti-inflammatory pathway could be modulated by negative energy balance and increased energy expenditure. This observation needs to be validated in larger cohorts of obese patients.
It is well known that nicotinic acid and catecholamines may regulate inflammation in adipose cells, 23, 25 but the variants of cholinergic receptor involved have not been clearly identified. In order to demonstrate a specific and direct anti-inflammatory action of a7nAChR stimulation, we thus used its specific agonist PNU282987. We showed for the first time that stimulation of a7nAChR is able to control inflammatory gene expression in SAT adipocytes in vitro, decreasing significantly the expression of IL6, MCP-1 and TNFa. HP and adiponectin gene expression levels were unaffected by the treatment and this could be probably due to the short-term stimulation and the low LPS concentration used. It will be certainly of interest to test the anti-inflammatory effects of a7nAChR stimulation at longer times. Usually, the receptor protein families (such as b-adrenoceptors, a-adrenoceptors, leptin receptors and R1/R2 adiponectin receptors) are ideal targets to develop a pharmacologic strategy for a disease. a7nAChR may represent a new potential target for the control of inflammation in human obesity. 8 Although a wide variety of cellular mechanisms may modulate a7nAChR functional activity, recently tyrosine-kinase de-phosphorylation has been shown to be the major pathway for a rapid upregulating effect on this receptor. 17 Indeed, a broad spectrum of protein tyrosinekinase inhibitors (such as genistein and daidzein) potentiates a7nAChR activity, increasing the number of surface a7nAChR rather than modulating the receptor's open state. 17 The results presented herein suggest that protein tyrosinekinase inhibitors, such as genistein, could be employed for a7nAChR upregulation and for the management of low-grade inflammation linked to human obesity. Further studies are certainly needed in large cohorts of obese patients to establish the therapeutic effects of genistein on a7nAChR activation and on circulating inflammatory cytokine modifications. a7nAChR in human adipocytes
